SCHEMBL5135644

SCHEMBL5135644

CCCCN(Cc1ccc(O)c([N+](=O)[O-])c1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
C5AR1 P21730 1/20 0.43
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
PDCD1 Q15116 1/20 0.37
CD274 Q9NZQ7 1/20 0.37
KDM4E B2RXH2 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
HDAC1 Q13547 1/20 0.36
ABCC1 P33527 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
TSHR P16473 1/20 0.35
TSPO P30536 1/20 0.35
HTR1A P08908 1/20 0.34
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
BCHE P06276 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137739 0.94 C5AR1 (0.43) POLBC5AR1ALDH1A1MAPTPDCD1
SCHEMBL5075065 0.93 C5AR1 (0.43) POLBC5AR1ALDH1A1MAPTPDCD1
SCHEMBL5138010 0.88 C5AR1 (0.41) POLBC5AR1ALDH1A1MAPTPDCD1
SCHEMBL5135247 0.87 C5AR1 (0.43) C5AR1ALDH1A1MAPTKDM4ETSHR
SCHEMBL649712 0.87 C5AR1 (0.49) C5AR1ALDH1A1KDM4EHDAC1TSHR
SCHEMBL650018 0.85 C5AR1 (0.46) C5AR1ALDH1A1KDM4EHDAC1TSHR
SCHEMBL650777 0.85 C5AR1 (0.46) C5AR1ALDH1A1KDM4EHDAC1TSHR
SCHEMBL5072432 0.84 C5AR1 (0.47) C5AR1ALDH1A1KDM4EHDAC1TSHR
SCHEMBL5074276 0.84 C5AR1 (0.47) C5AR1ALDH1A1KDM4EHDAC1TSHR
SCHEMBL648771 0.83 C5AR1 (0.45) C5AR1KDM4EHDAC1TSHRBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed